BACKGROUND: Aminoglycoside-induced ototoxicity has been reported in neonates but its incidence is poorly defined, whereas vancomycin-induced ototoxicity has not been reported in neonates. OBJECTIVE: To compare hearing test results in infants in a neonatal intensive care unit (NICU) who were or were not treated with extended interval gentamicin dosing and/or standard vancomycin dosing. METHOD: A database of otoacoustic emissions (OAE), over a 5-year period of NICU admissions, was combined with databases of gentamicin and vancomycin dosing to compare patients treated or not treated with these antibiotics. RESULTS: A total of 2,347 OAE results was available. OAE failure rates were: no gentamicin and no vancomycin (noGnoV), 7% (85/1,233); gentamicin but no vancomycin (GnoV), 4% (42/949); vancomycin but no gentamicin (VnoG), 22% (9/41) and gentamicin and vancomycin (GandV), 14% (17/124). Compared to noGnoV there was a decreased risk of OAE failure in GnoV (p = 0.022, OR 0.64, 95% CI 0.44-0.94) and an increased risk in VnoG (p = 0.003, OR 3.46, 95% CI 1.54-7.75) and GandV, (p = 0.006, OR 2.20, 95% CI 1.26-3.83). CONCLUSIONS: Gentamicin, as used and evaluated in this audit, showed no evidence of an increased risk of ototoxicity; what was observed was a statistically significant decrease in OAE failure rate. Vancomycin, by contrast, was associated with ototoxicity.
BACKGROUND:Aminoglycoside-induced ototoxicity has been reported in neonates but its incidence is poorly defined, whereas vancomycin-induced ototoxicity has not been reported in neonates. OBJECTIVE: To compare hearing test results in infants in a neonatal intensive care unit (NICU) who were or were not treated with extended interval gentamicin dosing and/or standard vancomycin dosing. METHOD: A database of otoacoustic emissions (OAE), over a 5-year period of NICU admissions, was combined with databases of gentamicin and vancomycin dosing to compare patients treated or not treated with these antibiotics. RESULTS: A total of 2,347 OAE results was available. OAE failure rates were: no gentamicin and no vancomycin (noGnoV), 7% (85/1,233); gentamicin but no vancomycin (GnoV), 4% (42/949); vancomycin but no gentamicin (VnoG), 22% (9/41) and gentamicin and vancomycin (GandV), 14% (17/124). Compared to noGnoV there was a decreased risk of OAE failure in GnoV (p = 0.022, OR 0.64, 95% CI 0.44-0.94) and an increased risk in VnoG (p = 0.003, OR 3.46, 95% CI 1.54-7.75) and GandV, (p = 0.006, OR 2.20, 95% CI 1.26-3.83). CONCLUSIONS:Gentamicin, as used and evaluated in this audit, showed no evidence of an increased risk of ototoxicity; what was observed was a statistically significant decrease in OAE failure rate. Vancomycin, by contrast, was associated with ototoxicity.
Authors: Angela C Garinis; Alison Kemph; Anne Marie Tharpe; Joern-Hendrik Weitkamp; Cynthia McEvoy; Peter S Steyger Journal: Int J Audiol Date: 2017-06-22 Impact factor: 2.117
Authors: Mihai Puia-Dumitrescu; Olivia M Bretzius; Nia Brown; James A Fitz-Henley; Rebecca Ssengonzi; Caroline S Wechsler; Keyaria D Gray; Daniel K Benjamin; P Brian Smith; Reese H Clark; Daniel Gonzalez; Christoph P Hornik Journal: J Pediatr Date: 2018-09-21 Impact factor: 4.406
Authors: Theresa Madigan; Christine B Teng; Jena Koshaish; Kent R Johnson; Kevin K Graner; Ritu Banerjee Journal: Am J Perinatol Date: 2014-05-16 Impact factor: 1.862
Authors: Jessica E Ericson; Joshua Thaden; Heather R Cross; Reese H Clark; Vance G Fowler; Daniel K Benjamin; Michael Cohen-Wolkowiez; Christoph P Hornik; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-04 Impact factor: 3.806